{
  "trial_id": "NCT00767520",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ethnicity, performance status, prior therapy with non-steroidal aromatase inhibitor, tumor histology, tumor stage, metastatic sites, prior treatments, baseline ejection fraction, baseline QTc interval, baseline hematologic parameters, baseline chemistry parameters, presence of significant comorbidities.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)",
          "performance status"
        ],
        [
          "Setting of Non-steroidal Aromatase Inhibitor",
          "prior therapy with non-steroidal aromatase inhibitor"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Time from Initial diagnosis to randomization",
        "Symptomatic Bone Disease"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "tumor histology",
        "tumor stage",
        "metastatic sites",
        "prior treatments",
        "baseline ejection fraction",
        "baseline QTc interval",
        "baseline hematologic parameters",
        "baseline chemistry parameters",
        "presence of significant comorbidities"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, performance status, prior therapy with non-steroidal aromatase inhibitor, tumor histology, tumor stage, metastatic sites, prior treatments, baseline ejection fraction, baseline QTc interval, baseline hematologic parameters, baseline chemistry parameters, presence of significant comorbidities."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, Performance Status, Prior therapy with non-steroidal aromatase inhibitor, Tumor histology, Metastatic sites, Prior chemotherapy, Prior radiotherapy, Baseline ejection fraction, Hematologic parameters, Chemistry parameters,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)",
          "Performance Status"
        ],
        [
          "Setting of Non-steroidal Aromatase Inhibitor",
          "Prior therapy with non-steroidal aromatase inhibitor"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Time from Initial diagnosis to randomization",
        "Symptomatic Bone Disease"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Tumor histology",
        "Metastatic sites",
        "Prior chemotherapy",
        "Prior radiotherapy",
        "Baseline ejection fraction",
        "Hematologic parameters",
        "Chemistry parameters"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Race/Ethnicity, Region of Enrollment, Performance Status, Prior therapy with non-steroidal aromatase inhibitor, Tumor histology, Metastatic sites, Prior chemotherapy, Prior radiotherapy, Baseline ejection fraction, Hematologic parameters, Chemistry parameters"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Menopausal Status, Prior Non-steroidal Aromatase Inhibitor (NSAI) Therapy, Prior Chemotherapy, Prior Radiation Therapy, Prior Hormone Therapy, Prior Targeted Therapy, Prior Bisphosphonate Therapy, Tumor Estrogen Receptor (ER) Status, Tumor Progesterone Receptor (PR) Status, Tumor Human Epidermal Growth Factor Receptor 2 (HER2) Status, Prior Breast Cancer Surgery, Prior Breast Cancer Radiation Therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)",
          "Eastern Cooperative Oncology Group (ECOG) Performance Status"
        ],
        [
          "Setting of Non-steroidal Aromatase Inhibitor",
          "Prior Non-steroidal Aromatase Inhibitor (NSAI) Therapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Time from Initial diagnosis to randomization",
        "Symptomatic Bone Disease"
      ],
      "remaining_candidate_features": [
        "Menopausal Status",
        "Prior Chemotherapy",
        "Prior Radiation Therapy",
        "Prior Hormone Therapy",
        "Prior Targeted Therapy",
        "Prior Bisphosphonate Therapy",
        "Tumor Estrogen Receptor (ER) Status",
        "Tumor Progesterone Receptor (PR) Status",
        "Tumor Human Epidermal Growth Factor Receptor 2 (HER2) Status",
        "Prior Breast Cancer Surgery",
        "Prior Breast Cancer Radiation Therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Menopausal Status, Prior Non-steroidal Aromatase Inhibitor (NSAI) Therapy, Prior Chemotherapy, Prior Radiation Therapy, Prior Hormone Therapy, Prior Targeted Therapy, Prior Bisphosphonate Therapy, Tumor Estrogen Receptor (ER) Status, Tumor Progesterone Receptor (PR) Status, Tumor Human Epidermal Growth Factor Receptor 2 (HER2) Status, Prior Breast Cancer Surgery, Prior Breast Cancer Radiation Therapy."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, performance status, body mass index, menopausal status, prior therapy with chemotherapy, radiotherapy, or hormonal therapy, prior exposure to Src-family kinase inhibitors, presence of metastases, tumor receptor status (ER, PR, HER2), prior surgery, lactose intolerance, history of cardiac conditions, bleeding disorders, gastrointestinal bleeding, hematologic abnormalities, chemistry abnormalities, Gilbert's disease.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)",
          "performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Time from Initial diagnosis to randomization",
        "Setting of Non-steroidal Aromatase Inhibitor",
        "Symptomatic Bone Disease"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index",
        "menopausal status",
        "prior therapy with chemotherapy",
        "radiotherapy",
        "or hormonal therapy",
        "prior exposure to Src-family kinase inhibitors",
        "presence of metastases",
        "tumor receptor status (ER, PR, HER2)",
        "prior surgery",
        "lactose intolerance",
        "history of cardiac conditions",
        "bleeding disorders",
        "gastrointestinal bleeding",
        "hematologic abnormalities",
        "chemistry abnormalities",
        "Gilbert's disease"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, performance status, body mass index, menopausal status, prior therapy with chemotherapy, radiotherapy, or hormonal therapy, prior exposure to Src-family kinase inhibitors, presence of metastases, tumor receptor status (ER, PR, HER2), prior surgery, lactose intolerance, history of cardiac conditions, bleeding disorders, gastrointestinal bleeding, hematologic abnormalities, chemistry abnormalities, Gilbert's disease."
  }
}